AstraZeneca Beats Expectations as Cancer Medicines Drive Strong Profit Growth
AstraZeneca reported better-than-expected earnings on the back of robust oncology sales and called for faster pharmaceutical innovation to keep pace with increasingly competitive Chinese drugmakers. The results provided support for London's stock market despite wider market uncertainty.